Late-Stage Trial in Chronic Hepatitis D Discontinued Due to Safety Concerns
Several trial participants experienced concerning hepatobiliary events.
Source: ajmc.com
Peginterferon Lambda News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Peginterferon Lambda. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Peginterferon Lambda Today - Breaking & Trending Today
Eiger scraps phase III but delta force deploying in hepatitis
One hepatitis delta virus player (HDV) has dropped out after Eiger Biopharmaceuticals Inc.’s phase III effort with peginterferon lambda turned up safety issues, while others remain busy in a space highlighted during last November’s meeting of the American Association for the Study of Liver Diseases. Shares of Palo Alto, Calif.-based Eiger (NASDAQ:EIGR) closed Sept. 13 at 41 cents, down 28 cents, or 40.6%, on word that the company is stopping the Limt-2 study in patients with chronic HDV.
Source: bioworld.com
Eiger Halts Phase 3 LIMT-2 Trial in Hepatitis D
The discontinuation of LIMT-2 was announced after 4 patients experienced hepatobiliary events resulting in liver decompensation during the phase 3 study of peginterferon lambda for HDV.
Source: hcplive.com
Eiger To Discontinue Peginterferon Lambda Trial In CHD Patients; Stock Down In Premarket
Eiger BioPharmaceuticals, Inc. (EIGR), a commercial-stage biopharmaceutical company focused on rare metabolic diseases, Wednesday said it has decided to discontinue the Phase 3 LIMT-2 study of peginterferon lambda in patients with chronic hepatitis delta or CHD.
Source: rttnews.com
Eiger BioPharmaceuticals Makes Interim CEO Permanent, It Chalks Out Portfolio Prioritization Review, Layoffs - Eiger BioPharmaceuticals (NASDAQ:EIGR)
Eiger BioPharmaceuticals Inc (NASDAQ: EIGR) announced it would focus its development efforts on advancing avexitide in
Source: benzinga.com